Covid-19 roundup: Hit with new conflict accusations, Janet Woodcock steps out of the agency's Covid-19 chain of command
Two weeks ago, FDA drug chieftain Janet Woodcock was assuring a top Wall Street analyst that any vaccine approved for combating Covid-19 would have to meet high agency standards on safety and efficacy before it’s approved. But over the weekend, after she and Peter Marks took top positions with the public-private operation meant to speed a new vaccine to lightning-fast approvals — they both recused themselves from the review process after an advocacy group argued their roles close to the White House could pose a conflict of interest.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.